Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
A ten-year comparison of Aristocrats ETFs highlights performance patterns, dividend consistency, and growth trajectory to aid selection.
27,377 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
XRP exchange-traded funds booked their first monthly net outflow after a $1.2 billion rally, signaling a shift in inv...
The NEOS Gold High Income ETF has surged about 24% since its debut, yet investors should weigh the income wrapper tha...
A traditional aerospace and defense ETF is delivering double-digit gains this year with no Tesla exposure, challengin...
In mid-2026, the Amplify CWP Enhanced Dividend Income ETF climbs past $5.25 billion in assets as its monthly distribu...
Rowe Price unveils an actively managed multi-crypto ETF on NYSE Arca, signaling traditional fund managers’ growing ap...
A popular fallen angel ETF delivers about 6% yield paid monthly by buying bonds downgraded from investment grade. It’...
Bitcoin trades near the $63,000 level as tariff-related policy shocks dampen ETF flows, keeping the crypto winter moo...
XRP’s leverage washout has cooled, but the next move hinges on real buying. ETFs and spot demand must prove durable t...
Bitcoin sits near the $65,000 mark as global headlines churn. This morning minute breaks down the drivers behind the ...
Looking ahead five years, XRP faces a mix of regulatory, market, and adoption factors. This article breaks down scena...
Bitcoin slips toward $65K as spot ETF outflows persist and on-chain risk builds, fueling talk that the cycle may slid...